2022 Drug Trend Report
Erx logo-01

Benefits of EpiphanyRx

EpiphanyRx, acquired by Navitus in 2021, is Navitus' in-house solution for self-insured employers with ~3000 lives or less. EpiphanyRx is a specialized division within Navitus.

  • Through the acquisition, EpiphanyRx clients realized a $28 PMPM or 30% cost reduction, compared to projected pre-acquisition costs, by leveraging Navitus' purchasing power for discounts and rebates.

EpiphanyRx provides a standard suite of products designed to decrease costs and support a rich benefit offering for employers of this size, for example:

  • One modular, cost-effective formulary with utilization management designed to drive results
  • Strategies to lower member and plan cost on both traditional and specialty drugs
image 24

 

The value of EpiphanyRx is demonstrated by the following:

ERx 5.7 average net total cost

 

Net Total Cost PMPM-01-01

 

Consistent with the overall Navitus book of business, targeted immunomodulators (TIMs) and diabetes were two primary drug class cost drivers for specialty and non-specialty respectively. Programs to drive down costs for these two drug classes is a key focus for 2023 and 2024.

To learn more about EpiphanyRx, visit EpiphanyRx.com.

1Net total cost paid by plans and members minus manufacturer rebates.

GET THE 2022 DRUG TREND EXECUTIVE SUMMARY

Download your free copy

home physician and patient